GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) declared a quarterly dividend on Wednesday, October 28th. Investors of record on Friday, November 13th will be given a dividend of $0.4518 per share by the pharmaceutical company on Thursday, January 7th. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.7%. The ex-dividend date is Friday, November 13th. This is a 0.1% increase from GSK’s previous quarterly dividend of $0.4515.
GSK has decreased its dividend payment by an average of 0.1% per year over the last three years. GSK has a dividend payout ratio of 36.6% meaning its dividend is sufficiently covered by earnings. Research analysts expect GSK to earn $5.00 per share next year, which means the company should continue to be able to cover its $1.77 annual dividend with an expected future payout ratio of 35.4%.
GSK Trading Down 4.4%
GSK opened at $48.71 on Thursday. The business’s 50 day moving average is $49.57 and its two-hundred day moving average is $52.35. GSK has a 52 week low of $45.50 and a 52 week high of $61.69. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The firm has a market cap of $98.52 billion, a price-to-earnings ratio of 15.23, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33.
GSK (NYSE:GSK – Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%. The business’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted $0.47 earnings per share. On average, research analysts predict that GSK will post 4.78 EPS for the current year.
About GSK
GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.
Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.
Featured Articles
- Five stocks we like better than GSK
- 1 Frozen Housing Market, 2 Very Different Earnings Stories
- 3 Energy Stocks Boosting Dividends as the Sector Widens Its 2026 Performance Lead
- Garmin Raises Its Profit OutlookâCan the Stock Reach New Highs?
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
